Gunnel Biberfeld

Q: What Schools Are Affiliated With Gunnel Biberfeld

Gunnel Biberfeld is affiliated with the following schools: Karolinska Institute, Muhimbili University of Health and Allied Sciences, University of Innsbruck, University of Dar es Salaam

Gunnel Biberfeld's AcademicInfluence.com Rankings

Gunnel Biberfeld

Philosophy

#8581

World Rank

#11990

Historical Rank

Logic

#5614

World Rank

#7025

Historical Rank

philosophy Degrees

Gunnel Biberfeld

Biology

#11658

World Rank

#15070

Historical Rank

Immunology

#761

World Rank

#783

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Gunnel Biberfeld Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gunnel Biberfeld's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION (1986) (455)
Prevention of Mother-to-Child Transmission of HIV-1 Through Breastfeeding by Treating Mothers With Triple Antiretroviral Therapy in Dar es Salaam, Tanzania: The Mitra Plus Study (2009) (240)
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys (1991) (204)
HIV Counseling and Testing of Pregnant Women in Sub‐Saharan Africa: Experiences From a Study on Prevention of Mother‐to‐Child HIV‐1 Transmission in Dar Es Salaam, Tanzania (2001) (204)
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection (1987) (176)
Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. (1976) (174)
Ultrastructural Features of Mycoplasma pneumoniae (1970) (173)
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. (2008) (165)
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. (2000) (163)
Antibodies to brain and other tissues in cases of Mycoplasma pneumoniae infection. (1971) (160)
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure (2000) (154)
HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. (1986) (153)
Prevention of Mother-to-Child Transmission of HIV-1 Through Breast-Feeding by Treating Infants Prophylactically With Lamivudine in Dar es Salaam, Tanzania: The Mitra Study (2008) (136)
Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. (1997) (136)
Mycoplasma pneumoniae is a polyclonal B-cell activator (1976) (128)
A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. (1987) (122)
Prevalence of HIV-1 infection in the Kagera region of Tanzania: a population-based study. (1990) (118)
T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella (1983) (113)
Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania (2013) (112)
Immunological changes in primary HIV‐1 infection (1990) (111)
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. (2011) (110)
Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. (1987) (105)
A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. (1993) (102)
Oral candida albicans in HIV infection. (1987) (100)
Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. (1993) (99)
Discrimination between antibodies to HIV and to related retroviruses using site-directed serology (1987) (98)
BLOOD DONOR SERA WITH FALSE-POSITIVE WESTERN BLOT REACTIONS TO HUMAN IMMUNODEFICIENCY VIRUS (1986) (89)
Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. (1999) (89)
Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV‐1 and HIV‐2 infections in an HIV‐1 and HIV‐2‐prevalent area (1997) (88)
Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm (1998) (87)
Malignant lymphomas in cynomolgus monkeys infected with simian immunodeficiency virus. (1990) (86)
Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. (2001) (81)
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. (2009) (79)
Central nervous system complications of Mycoplasma pneumoniae infection. (1969) (76)
Immunohistopathology of lymph nodes in HTLV-III infected homosexuals with persistent adenopathy or AIDS. (1985) (75)
New human and simian HIV-related retroviruses possess functional transactivator (tat) gene (1987) (74)
Performance of a modified HIV-1 p24 antigen assay for early diagnosis of HIV-1 infection in infants and prediction of mother-to-infant transmission of HIV-1 in Dar es Salaam, Tanzania. (1996) (71)
A monkey model for Epstein Barr virus-associated lymphomagenesis in human acquired immunodeficiency syndrome [published erratum appears in J Exp Med 1992 Aug 1;176(2):following 634] (1992) (70)
Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. (1990) (69)
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. (2004) (69)
Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from guinea-bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa. (1999) (68)
Long–term protection against SIV–induced disease in macaques vaccinated with a live attenuated HIV–2 vaccine (1995) (68)
Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. (1989) (68)
Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. (1989) (67)
Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site (1990) (66)
Activation of Human Lymphocyte Subpopulations by Mycoplasma pneumoniae (1977) (64)
Women's Preferences Regarding Infant or Maternal Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission of HIV during Breastfeeding and Their Views on Option B+ in Dar es Salaam, Tanzania (2014) (64)
Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. (1996) (64)
Vaccine protection against HIV-2 infection in cynomolgus monkeys. (1991) (63)
A new method for measuring lymphoproliferation at the single-cell level in whole blood cultures by flow cytometry. (1996) (63)
Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. (1986) (62)
Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission (1997) (61)
Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation (2010) (61)
Optimal Blood Mononuclear Cell Isolation Procedures for Gamma Interferon Enzyme-Linked Immunospot Testing of Healthy Swedish and Tanzanian Subjects (2008) (61)
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. (1996) (60)
Circulating immune complexes in Mycoplasma pneumoniae infection. (1974) (60)
Histopathology and immunohistology of HTLV-III/LAV related lymphadenopathy and AIDS. (2009) (59)
Incidence of HIV-1 infection among adults in the Kagera region of Tanzania. (1993) (57)
Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. (1996) (57)
Affordable CD4+ T cell counts by flow cytometry. II. The use of fixed whole blood in resource-poor settings. (2001) (57)
The effect of irradiation on T-cell suppression of ELISA-determined Ig production by human blood B-cells in vitro. (1979) (57)
Decline in the prevalence of HIV-1 infection in young women in the Kagera region of Tanzania. (1998) (56)
Acceptability of voluntary HIV testing with counselling in a rural village in Kagera, Tanzania. (1998) (55)
A Plaque Technique for Assay and Characterization of Antibody‐Dependent Cytotoxic Effector (K) Cells (1975) (55)
Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel. (1998) (55)
Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania (2004) (54)
ANTIBODY RESPONSES IN MYCOPLASMA PNEUMONIAE INFECTION IN RELATION TO SERUM IMMUNOGLOBULINS, ESPECIALLY IgM (2009) (52)
Cell-mediated immune response following Mycoplasma pneumoniae infection in man. I. Lymphocyte stimulation. (1974) (52)
A novel assay for assessment of HIV‐specific cytotoxicity by multiparameter flow cytometry (2005) (52)
Lymphocyte subset enumeration in HIV seronegative and HIV-1 seropositive adults in Dar es Salaam, Tanzania: determination of reference values in males and females and comparison of two flow cytometric methods. (2003) (51)
Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience (2009) (50)
Fixation of cell-bound antibody in the membrane immunofluorescence test. (1974) (50)
HIV-1, HIV-2, HTLV-I/II and Treponema pallidum infections: incidence, prevalence, and HIV-2-associated mortality in an occupational cohort in Guinea-Bissau. (1995) (50)
Cytological observations on the cytotoxic interaction between lymphocytes and antibody-coated monolayer cells. (1973) (50)
Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania (2015) (50)
Alternative confirmatory strategies in HIV-1 antibody testing. (1992) (49)
Clinical features and predictive markers of disease progression in cynomolgus monkeys experimentally infected with simian immunodeficiency virus (1992) (48)
A capture enzyme immunoassay for detection of HIV-2/SIV antigen. (1991) (47)
Sexual behaviour among youths at high risk for HIV-1 infection in Dar es Salaam, Tanzania (2001) (46)
Monitoring of HIV-1 infection prevalence and trends in the general population using pregnant women as a sentinel population: 9 years experience from the Kagera region of Tanzania. (2000) (46)
Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. (1990) (46)
Reaction of human smooth muscle antibodies with human blood lymphocytes and lymphoid cell lines (1974) (45)
Beta-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. (1999) (45)
Specific and non-specific B cell activation in measles and varicella. (1983) (45)
Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998–1999 (2007) (44)
Smooth muscle antibodies in Mycoplasma pneumoniae infection. (1976) (43)
HIV-1 Infection Prevalence and Incidence Trends in Areas of Contrasting Levels of Infection in the Kagera Region, Tanzania, 1987-2000 (2005) (43)
Evaluation of an alternative confirmatory strategy for the diagnosis of HIV infection in Dar Es Salaam, Tanzania, based on simple rapid assays. (2002) (42)
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial (2015) (42)
Malignant lymphoma associated with human AIDS and with SIV-induced immunodeficiency in macaques. (1992) (41)
Experimental infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus (SIVsm). (1989) (41)
Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults (2015) (41)
Comparative evaluation of 14 immunoassays for detection of antibodies to the human T‐lymphotropic virus types I and II using panels of sera from Sweden and West Africa (1999) (41)
A study of Mycoplasma pneumoniae infections in families. (1969) (41)
Monitoring of HIV‐1 Infection Prevalence and Trends in the General Population Using Pregnant Women as a Sentinel Population: 9 Years Experience From the Kagera Region of Tanzania (2000) (40)
Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection (2001) (40)
HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial (2015) (39)
Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1. (1991) (39)
Strong HIV-Specific CD4+ and CD8+ T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes (2010) (39)
Prevalence of HIV infection in healthy subjects and groups of patients in Tanzania. (1987) (38)
Evaluation of a prototype Amplicor PCR assay for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults infected with HIV-1 subtypes A, C and D. (2000) (38)
High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. (1999) (38)
The accuracy of an alternative confirmatory strategy for detection of antibodies to HIV-1: experience from a regional laboratory in Kagera, Tanzania. (1999) (37)
Late postnatal transmission of human immunodeficiency virus type 1 infection from mothers to infants in Dar es Salaam, Tanzania. (1997) (35)
Improved Detection of HIV‐2 DNA in Clinical Samples Using a Nested Primer‐Based Polymerase Chain Reaction (1992) (35)
Radioimmunoprecipitation and Western blotting with sera of human immunodeficiency virus infected patients: a comparative study. (1987) (35)
Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994. (1997) (35)
ABSENCE OF ANTIBODIES TO LAV/HTLV-III IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATE OF AMERICAN ORIGIN (1985) (35)
Prevalence of HIV‐1 Infection and Symptomatology of AIDS in Severely Malnourished Children in Dar Es Salaam, Tanzania (1991) (35)
HIV-2-associated AIDS and HIV-2 seroprevalence in Bissau, Guinea-Bissau. (1989) (35)
Genetic analysis of a new subgroup of human and simian T-lymphotropic retroviruses: HTLV-IV, LAV-2, SBL-6669, and STLV-IIIAGM. (1987) (34)
Distribution of antibodies within 19 S and 7 S immunoglobulins following infection with Mycoplasma pneumoniae. (1968) (34)
The Prevalence and Pattern of Skin Diseases in Relation to CD4 Counts Among HIV-Infected Police Officers in Dar es Salaam (2003) (33)
HIV-2 infection in hospitalized patients in Bissau, Guinea-Bissau. (1991) (33)
B‐cell lymphomagenesis in SIV‐immunosuppressed cynomolgus monkeys (1995) (32)
Surface immunoglobulin light chain determinants on normal and PHA-stimulated human blood lymphocytes studied by immunofluorescence and electronmicroscopy. (1971) (32)
Innate immunity in experimental SIV infection and vaccination. (2005) (32)
STUDIES ON MYCOPLASMA PNEUMONIAE INFECTION IN SWEDEN. (1965) (32)
Detection of antibodies which mediate human immunodeficiency virus-specific cellular cytotoxicity (ADCC) in vitro. (1987) (31)
Evaluation of the WHO human immunodeficiency virus (HIV) antibody testing strategy for the diagnosis of HIV infection. (1994) (31)
Reaction of human smooth muscle antibody with thymus medullary cells. (1973) (31)
8 – INFECTION SEQUELAE AND AUTOIMMUNE REACTIONS IN Mycoplasma pneumoniae INFECTION (1985) (30)
High HIV seroprevalence and increased HIV‐associated mortality among hospitalized patients with deep bacterial infections in Dar es Salaam, Tanzania (1992) (30)
Non-specific polyclonal antibody response induced by Mycoplasma pneumoniae. (1983) (30)
Antibodies in bronchial secretions following natural infection with Mycoplasma pneumoniae. (2009) (29)
Measurement of lymphoproliferation at the single-cell level by flow cytometry. (2000) (28)
Tuberculin anergy in patients with Mycoplasma pneumoniae infection. (1976) (28)
Prevalence of HIV type 1 infection, associated clinical features and mortality among hospitalized children in Dar es Salaam, Tanzania. (2000) (28)
Prevalence and Incidence of Syphilis and its Association with HIV-1 Infection in a Population-Based Study in the Kagera Region of Tanzania (1994) (28)
T lymphocyte subpopulations in synovial fluid of patients with rheumatic disease. (1979) (27)
High frequency of sexually transmitted diseases among pregnant women in Dar es Salaam, Tanzania: need for intervention. (1996) (27)
Expression of epstein‐barr‐virus‐related nuclear antigens and B‐cell markers in lymphomas of SIV‐immunosuppressed monkeys (1993) (27)
Prevalence of HIV infection among hospital patients in north west Tanzania. (1999) (26)
HTLV-I and -II infections in a nationwide survey of pregnant women in Guinea-Bissau, West Africa. (1997) (26)
Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. (1994) (26)
FINDINGS IN FOUR HTLV-IV SEROPOSITIVE WOMEN FROM WEST AFRICA (1986) (25)
A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge. (1992) (25)
Job satisfaction and turnover intentions among health care staff providing services for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania (2017) (25)
Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults (1997) (25)
Characterization of malignant and non‐neoplastic cell phenotypes in highly malignant non‐Hodgkin lymphomas (1983) (25)
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. (2007) (25)
Incidence of HIV and the Prevalence of HIV, Hepatitis B and Syphilis among Youths in Maputo, Mozambique: A Cohort Study (2015) (25)
A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice. (2007) (25)
Pulmonary tuberculosis in Guinea-Bissau: clinical and bacteriological findings, human immunodeficiency virus status and short term survival of hospitalized patients. (1996) (24)
Thymic immunopathology and progression of SIVsm infection in cynomolgus monkeys. (1995) (24)
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design (2018) (24)
Sexually transmitted viral infections in various population groups in Mogadishu, Somalia. (1987) (24)
Transmission of HIV infection to heterosexual partners but not to household contacts of seropositive haemophiliacs. (1986) (24)
Lack of cross-reaction in antibody-dependent cellular cytotoxicity between human immunodeficiency virus (HIV) and HIV-related West African strains. (1988) (24)
Macrophage migration inhibition in response to experimental mycoplasma pneumoniae infection in the hamster (1973) (24)
Treatment of Kaposi Sarcoma in Human Immunodeficiency Virus-1-infected Mozambican Children With Antiretroviral Drugs and Chemotherapy (2011) (24)
Mitogen‐Induced Switching of Immunoglobulin Heavy‐Chain Class Secretion in Chronic B‐Lymphocytic Leukaemia and Immunocytoma Cell Populations (1983) (24)
NONVERTICAL, NONSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS IN CHILDREN (2010) (23)
Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I. (1988) (23)
Clinical features, immunological changes and mortality in a cohort of HIV-2-infected individuals in Bissau, Guinea-Bissau. (1998) (23)
A T lymphocyte subpopulation in multiple sclerosis patients bearing Fc receptors for both IgG and IgM1. (1980) (22)
Spontaneous production of RANTES and antigen‐specific IFN‐γ production in macaques vaccinated with SHIV‐4 correlates with protection against SIVsm challenge (2002) (22)
Monocyte/macrophage giant cell disease in SIV-infected cynomolgus monkeys. (1991) (22)
Evaluation of HIV antibody and antigen/antibody combination ELISAs for use in an alternative confirmatory HIV testing strategy in Dar es Salaam, Tanzania. (2006) (22)
Mycoplasma pneumoniae infection in hospitalized patients with acute respiratory illness. (2009) (21)
Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. (2001) (21)
Efficacy of inactivated whole HIV‐2 vaccines with various adjuvants in cynomolgus monkeys (1994) (21)
Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines. (2000) (21)
Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies. (1995) (21)
T lymphocyte subpopulations defined by monoclonal antibodies in synovial fluid of patients with rheumatic disease. (1982) (21)
Clinical Progression in Early and Late Stages of Disease in a Cohort of Individuals Infected with Human Immunodeficiency Virus-2 in Guinea-Bissau (2003) (21)
Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135). (1989) (20)
Cell-mediated immune response following Mycoplasma pneumoniae infection in man. II. Leucocyte migration inhibition. (1974) (20)
Lymphadenopathy in HIV (HTLV-III/LAV) infected subjects: the role of virus and follicular dendritic cells. (1988) (19)
Enzyme immunoassays for the demonstration of antibodies to HIV-2SBL-6669 and HTLV-IV (SIVmac). (1988) (19)
Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells. (1993) (19)
Report of a consensus workshop, Siena, Italy, January 17-18, 1992. Early diagnosis of HIV infection in infants. (1992) (19)
Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. (2014) (19)
Immunohistochemical distribution of leucocyte antigens in lymphoid tissues of cynomolgus monkeys (Macaca fascicularis). (1993) (19)
Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. (2016) (19)
WHO Working Group on Characterization of HIV-Related Retroviruses: criteria for characterization and proposal for a nomenclature system. (1987) (18)
Reaction of human smooth muscle antibody with thyroid cells. (1974) (18)
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial (2016) (18)
Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques (2011) (18)
Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally Infected with simian immunodeficiency virus (SIVsm). (2001) (18)
The chemistry of site-directed serology for HIV infections. (1989) (18)
CHRONIC ACTIVE HEPATITIS IN CHILDREN A Clinical and Immunological Long‐term Study (1977) (17)
Intradermal testing with multiple recall antigens for identification of cell-mediated immune deficiency in homosexual men. (1986) (17)
Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. (2002) (17)
Antibodies to Surface Antigens of Lymphocytes and Lymphoblastoid Cells in Cold‐Agglutinin‐Positive Sera from Patients with Mycoplasma pneutnoniae Infection (1976) (17)
Identification of three FcR-positive T cell subsets (T gamma, T mu and T gamma mu) in the cerebrospinal fluid of multiple sclerosis patients. (1980) (17)
The Natural Course of Disease Following HIV-1 Infection in Dar es Salaam, Tanzania: A Study among Hotel Workers Relating Clinical Events to CD4+ T-lymphocyte Counts (2004) (17)
Selection of primers of optimal sensitivity for the detection of HIV-1 from Africa and Europe by polymerase chain reaction. (1991) (17)
Dichotomy between CD1a+ and CD83+ dendritic cells in lymph nodes during SIV infection of macaques (2004) (17)
HIV-1 and HIV-2 antibodies in pregnant women in the City of Maputo, Mozambique. A comparative study between 1982/1983 and 1990. (1993) (16)
Blood group antibodies as a source of error in the diagnosis of pemphigus by indirect immunofluorescence. (1972) (16)
Role of CD8+ Cell‐Produced Anti‐Viral Factors in Protective Immunity in HIV‐2‐Exposed but Seronegative Macaques Resistant to Intrarectal SIVsm Challenge (2001) (16)
The introduction of HIV during 1979-80 in a sexually active homosexual population of Stockholm. (1987) (16)
Konzo, an epidemic spastic paraparesis in Africa, is not associated with antibodies to HTLV-I, HIV, or HIV gag-encoded proteins. (1996) (16)
Autologous neutralizing antibodies to SIVsm in cynomolgus monkeys correlate to prognosis. (1993) (16)
Accessory cells and macrophages in the histopathology of SIVsm-infected cynomolgus monkeys. (1993) (16)
Association between HTLV-1 and HIV-2 infections in Bissau, Guinea-Bissau. (1992) (16)
Site-directed enzyme-linked immunosorbent assay with a synthetic simian immunodeficiency virus SIVmac peptide identifying antibodies against the HIV-2 transmembrane glycoprotein. (1989) (16)
Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates (1989) (15)
Vaccine studies with the 32H reisolate of SIVmac251: an overview. (1992) (15)
Clinical and immunological follow-up of previously hospitalized HIV-2 seropositive patients in Bissau, Guinea-Bissau. (1992) (15)
Dropouts in a Long‐Term Follow‐Up Study Involving Voluntary Counseling And HIV Testing: Experience From a Cohort of Police Officers in Dar Es Salaam, Tanzania (2002) (15)
Evaluation of commercial enzyme immunoassays for anti-HIV-1 using East African sera. (1988) (15)
Immunological profile of endemic and epidemic Kaposi's sarcoma patients in Dar-es-Salaam, Tanzania. (1998) (15)
Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. (2017) (15)
CLINICAL CASE DEFINITION OF AIDS IN AFRICAN ADULTS (1987) (15)
Immunohaematological findings in healthy and HIV-1 infected adults in Dar es Salaam, Tanzania. (1996) (14)
Prevalence of HIV-1 and HIV-2/HTLV-IV infections in Luanda and Cabinda, Angola. (1988) (14)
Evaluation of T Cell Subsets by an Immunocytochemical Method Compared to Flow Cytometry in Four Countries (1997) (14)
The mixed haemadsorption test as an aid to the diagnosis of thyroid autoimmune disease. (1968) (14)
HTLV-III infection in homosexuals and hemophiliacs in Sweden. (1985) (14)
The potential of task-shifting in scaling up services for prevention of mother-to-child transmission of HIV: a time and motion study in Dar es Salaam, Tanzania (2017) (14)
Nested PCR assays with novel primers yield greater sensitivity to Tanzanian HIV-1 samples than a commercial PCR detection kit. (1996) (13)
Mother‐to‐Child Transmission of HIV‐1 (2001) (13)
Cell-mediated immunity to low doses of SIVsm in cynomolgus macaques did not confer protection against mucosal rechallenge. (2000) (13)
Recruitment of monocyte derived dendritic cells ex vivo from SIV infected and non-infected cynomolgus monkeys. (2000) (13)
HIV‐serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs (1988) (13)
Predictors of Patient Dissatisfaction with Services for Prevention of Mother-To-Child Transmission of HIV in Dar es Salaam, Tanzania (2016) (13)
Autoimmune reactions associated with Mycoplasma pneumoniae infection. (1979) (13)
High sexual risk taking and diverging trends of HIV-1 and HIV-2 in the military of Guinea Bissau. (2010) (13)
The effect of in vitro irradiation on PHA-mediated cytotoxicity and lymphocytes with receptors for the Fc part of Ig. (1979) (13)
ANTIBODIES TO HTLV-IV ASSOCIATED WITH CHRONIC, FATAL ILLNESS RESEMBLING "SLIM" DISEASE (1986) (12)
Increased prevalence of HIV-2 infection in hospitalized patients with severe bacterial diseases in Guinea-Bissau. (1997) (12)
Antigen‐Specific β‐Chemokine Production and CD8+ T‐Cell Noncytotoxic Antiviral Activity in HIV‐2‐Infected Individuals (2005) (11)
Slow progression of HIV-1 infection in a cohort of antiretroviral naïve hotel workers in Dar es Salaam, Tanzania as defined by their CD4 cell slopes (2008) (11)
High mortality and severe immunosuppression in hospitalized patients with pulmonary tuberculosis and HIV-2 infection in Guinea-Bissau. (2001) (11)
The reaction of cells with anti-actin sera in relation to the amount of cellular actin. (1977) (11)
Proliferation and apoptosis-related gene expression in experimental acquired immunodeficiency syndrome-related simian lymphoma. (1999) (11)
Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques. (1994) (11)
Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. (1996) (11)
Antibodies against Mycoplasma pneumoniae in bronchial secretions. (2009) (11)
HTLV infections among Swedish intravenous drug users in 1992. (1995) (10)
Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating infants or mothers prophylactically with antiretrovirals in Dar es Salaam, Tanzania: the MITRA and MITRA PLUS studies (2008) (10)
Early diagnosis of HIV-1 infection in infants in Dar es Salaam, Tanzania. (1995) (10)
Autoantibodies to the basal cells of squamous epithelium react with thymic epithelial cells. (1985) (10)
Comparison of the performance of rapid HIV tests using samples collected for surveillance in Mozambique (2009) (10)
Early Case of Acquired Immunodeficiency Syndrome in a Child from Zaire (1986) (10)
Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam. (2009) (9)
HIV infection in a defined population of Swedish haemophiliacs. (1987) (9)
Dropouts in a long-term follow-up study involving voluntary counseling and HIV testing: experience from a cohort of police officers in Dar Es Salaam, Tanzania. (2002) (9)
Predictive markers of AIDS: a follow-up of lymphocyte subsets and HIV serology in a cohort of patients with lymphadenopathy. (1989) (8)
Mortality During the First 24 Months After Delivery in Relation to CD4 T-Lymphocyte Levels and Viral Load in a Cohort of Breast-Feeding HIV-1-Infected Women in Dar es Salaam, Tanzania (2005) (8)
Optimization of polymerase chain reaction for detection of HIV type 2 DNA. (1998) (8)
Response to Podophyllotoxin Treatment of Genital Warts in Relation to HIV-1 Infection among Patients in Dar Es Salaam, Tanzania (1995) (8)
Antibodies to Human T Lymphotropic Virus Type III Demonstrated by a Dot Immunobinding Assay (1985) (8)
Estimation of CD4 T-lymphocyte counts from percent CD4 T-lymphocyte determinations in HIV-1-infected subjects in sub-Saharan Africa (2003) (8)
SIV infection of monkey spleen cells including follicular dendritic cells in different stages of disease. (1996) (8)
PPD-induced viral antibody production in human blood lymphocytes. (1980) (8)
Large-scale evaluation of an alternative strategy for confirmation of HIV antibodies. (1995) (8)
Three-year follow-up of patients with pulmonary tuberculosis in Guinea-Bissau, West Africa. (2000) (7)
Progress with HIV vaccines. (1991) (7)
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen (2012) (7)
Autoantibodies to thymic epithelial cells in hepatitis B virus-associated delta infection. (1985) (7)
Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study. (2021) (7)
Autoantibodies against the basal cell layer: an association with chronic hepatitis B. (1983) (7)
Mycoplasma pneumoniae infections and antibodies to brain. (1969) (7)
HIV-2 Infection in Prenatal Women in Guinea-Bissau (1989) (7)
The role of HIV infection in pregnancy wastage in Dar es Salaam, Tanzania. (1992) (7)
Nested polymerase chain reaction primers that distinguish between SIVSM and HIV type 2. (1996) (7)
Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost (2020) (7)
Effect ofMycoplasma pneumoniae infection on cell-mediated immunity (2005) (6)
Immunosuppression and alterations of T-lymphocyte subpopulations after rubella vaccination (1980) (6)
A Prospective Study of Immunoglobulin Changes in Relation to Human Immunodeficiency Virus Infection in a Cohort of Homosexual Men (1989) (6)
Engaging community leaders to improve male partner participation in the prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania (2018) (6)
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers (2020) (6)
P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA (2009) (6)
[Primary LAV/HTLV-III infection--a febrile lymphatic gland disease with sore throat]. (1985) (5)
Differences in the distribution of synovial T lymphocyte subpopulations between patients with acute and chronic exudative synovitis. (1984) (5)
Radiosensitive t cell suppression in relation to the TG cell level in synovial fluid of patients with rheumatic disease. (1982) (5)
The intrarenal vascular alterations in nephrotoxic serum nephritis and their relationship to the development of hypertension. (2009) (5)
T‐Cell Helper Activity and B‐Cell Function of Synovial and Blood Lymphocytes from Patients with Rheumatoid Arthritis or Other Forms of Chronic Arthritis (1986) (5)
Human immunodeficiency virus (HIV)‐2‐specific T lymphocyte proliferative responses in HIV‐2‐infected and in HIV‐2‐exposed but uninfected individuals in Guinea‐Bissau (2005) (5)
Autoantibodies to thymic epithelial cells in HDV infection. (1987) (5)
Immunoregulatory Function of T8 and T4 Cells from Synovial Fluid and Blood of Patients with Rheumatoid Arthritis or Other Forms of Chronic Arthritis (1986) (4)
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers (2020) (4)
DEMONSTRATION OF ANTIBODIES AGAINST MYCOPLASMA PNEUMONIAE IN BRONCHIAL SECRETIONS BY IMMUNOFLUORESCENCE * (1971) (4)
Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults (2012) (4)
T8 cell suppression of antigen- and mitogen-induced T4 cell dependent immunoglobulin production. (1986) (4)
Transmission of HIV-2 in a west African family household. (1988) (4)
Prospects of vaccination as a means of preventing mother‐to‐child transmission of HIV‐I * (2002) (4)
HIV-antibody testings among injecting drug users (IDUs) in the Stockholm area, 1984-91: information compiled from testing laboratories. (1993) (4)
Some Aspects on the Epidemiology of AIDS and Infections with the Human Immunodeficiency Virus in the United Republic of Tanzania (1988) (4)
Anti-actin antibodies of human and rabbit origin. (1978) (3)
Suppressor T cells in mycosis fungoides and so-called premycotic eruptions. (1980) (3)
Virological findings during the smallpox outbreak in Stockholm in 1963. (2009) (3)
Screening of African sera stored for more than 17 years for HIV antibodies by site-directed serology (1989) (3)
[Venereological study in Stockholm: 1 in 3 homosexual men had infections requiring treatment]. (1984) (3)
HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV (2017) (3)
Subpopulations of T lymphocytes in patients with ankylosing spondylitis. (1980) (3)
Adoption of Safer Sexual Behavior by an HIV High Risk Group of Bar and Restaurant Workers in Dar es Salaam, Tanzania (1989) (3)
Similar birthweight in children born to HIV‐2 infected and HIV‐negative women in Guinea‐Bissau (1998) (3)
T lymphocyte subpopulations defined by monoclonal antibodies and FC receptor binding in relation to immunosuppression in vaccine-induced rubella infection. (2009) (3)
THE IMPACT OF HAEMOPHILUS INFLUENZAE SEROTYPE B RESURGENCE ON THE EPIDEMIOLOGY OF CHILDHOOD INVASIVE HAEMOPHILUS INFLUENZAE DISEASE IN ENGLAND AND WALES (2011) (3)
Eular workshop on Rheumatology Research (1982) (2)
Alteration of T lymphocyte subpopulations in Swedish hemophiliacs. (2009) (2)
Pathology of the Lymphoid System in Cynomolgus Monkeys Infected with SIVsm (1993) (2)
A Plaque Technique for Assay and Characterization of Antibody‐Dependent Cytotoxic Effector (K) Cells (1975) (2)
Child survival in children born to HIV-2 infected women in Guinea-Bissau, West Africa. (1999) (2)
International mycoplasma symposium 6/7th September 1971 in Mainz Summaries of the papers (1972) (2)
Prognostic significance of immunoglobulin isotype expression in B-cell non-Hodgkin’s lymphoma (1988) (2)
Monitoring Immune Function (2002) (2)
CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization (2012) (2)
OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees (2009) (2)
Reaction of anti-actin antibodies with lymphoid cells. (1980) (2)
Intradermal Electroporation of HIV-DNA Vaccine Followed by HIV-MVA Boost with or Without Addition of GLA Adjuvanted gp140 (2016) (1)
[Opportunistic malignant lymphomas in SIV infected primates--a model for Epstein-Barr virus associated lymphomas in AIDS]. (1992) (1)
Demonstration of antibodies to double-stranded DNA by the Crithidia luciliae immunofluorescence test. (1980) (1)
False-positive reaction by Wellcozyme anti-HIV ELISA. (1988) (1)
HHV8 AND OTHER HERPES VIRUS IN BIOPSIES OF AIDS RELATED AND ENDEMIC KAPOSI'S SARCOMA (KS) AND MALIGNANT LYMPHOMA: 33 (1997) (1)
SIV infection of follicular dendritic cells (FDC) and other spleen cell subsets in experimentally infected cynomolgus monkeys. (1995) (1)
Stabilization of HIV-1 Seroprevalence in Pregnant Women in Dar es Salaam, Tanzania: Towards Reaching a Plateau Phase? (1996) (1)
HIV-2 vaccine trials in cynomolgus monkeys. (1996) (1)
Health care costs associated with clinic visits for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania (2021) (1)
Effect of Mycoplasma pheumoniae infection on cell-mediated immunity. (1976) (1)
Proliferation and apoptosis-related gene expression in experimental Aids-related simian lymphoma. (1998) (1)
[HTLV-III infections and AIDS--current epidemiology and serology]. (1985) (1)
[LAV/HTLV-III--new discoveries on its properties, isolation, vaccination and therapy]. (1985) (1)
Vertical HIV transmission within 18 months post partum among women on lifelong antiretroviral therapy for HIV in Dar es Salaam, Tanzania: a prospective cohort study. (2022) (1)
Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults (2012) (1)
Immunoregulatory function of T8 and T4 cells from synovial fluid of patients with chronic arthritis (1986) (1)
Original article Sexual behaviour among youths at high risk for HIV-1 infection in Dar es Salaam, Tanzania (2001) (1)
Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine (2012) (1)
[Antibodies against AIDS-associated virus detected in a Swedish woman]. (1984) (0)
[Auto-antibodies in diagnosis]. (1968) (0)
PREVENTIVE HIV VACCINES: CURRENT STATUS (2002) (0)
The incidence of autoantibodies in a group of apparently healthy people. (1968) (0)
CHAPTER VI: INCIDENCE OF THYROID AUTOANTIBODIES AND ITS CORRELATION WITH CYTOLOGICAL FINDINGS IN LYMHOID THYROIDITIS IN ADULTS (2009) (0)
HIV-1 Specific CD4 and CD8 T-cell Responses Associated With Low Viral Load in Treatment-Naïve HIV-1 Infected Individuals (2005) (0)
[Two different HIV types are known. The differences may explain mechanisms of the infection]. (1996) (0)
[Autoimmune diseases and immune complex diseases]. (1975) (0)
[LAV/HTLV III infection in homosexual and bisexual men--data on transmission and risk markers in Stockholm]. (1986) (0)
Rising Prevalence of HIV Infection and General Attitude to Condom Utilisation Among Restaurant and Bar Workers in Dar es Salaam City (1988) (0)
Neutralizing antibodies inrelation toantibody-dependent cellular cytotoxicity-ind ucing antibodies against humanimmunodeficiency virus typeI (1988) (0)
Cellular Cytotoxicity Detects Type-andStrain- Specific Antigens amongHumanImmunodeficiency Virus Types1 and2andSimian Immunodeficiency VirusSlVmac Isolates (1989) (0)
Reactivity of sera from patients with liver disease with glutaraldehyde-treated erythrocytes: role for false positive results in hemagglutination tests. (1984) (0)
[Update on AIDS--virology, immunology, epidemiology]. (1984) (0)
Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen (2012) (0)
ANIMAL MODELS OF NEOPLASMS IN ACQUIRED IMMUNODEFICIENCY (1999) (0)
Sören possible effect of the civil war 1998-1999 pregnant women in Guinea-Bissau , West Africa : Trends of HIV-1 and HIV-2 prevalence among (2007) (0)
Correction (1992) (0)
Effect of peer-mother interactive programme on prevention of mother-to-child HIV transmission outcomes among pregnant women on anti-retroviral treatment in routine healthcare in Dar es Salaam, Tanzania (2022) (0)
Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine (2012) (0)
P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques (2009) (0)
LYMPHOMAGENESIS IN A SIMIAN AIDS MODEL: ABSTRACT 52 (2000) (0)
Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime (2012) (0)
[The first 2 fatal cases of AIDS in Sweden--diagnostic and therapeutic experiences]. (1984) (0)
HIV-1 Infection Among Tanzanian Pregnant Women in Dar-es-Salaam, Tanzania (1995) (0)
["Eaton agent" and primary atypical pneumonia]. (1965) (0)
P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers (2009) (0)
SHORT COMMUNICATION: Selection of primers of optimal sensitivity for the detection of HIV‐1 from Africa and Europe by polymerase chain reaction (1991) (0)
[A simple method for determination of antibodies to AIDS associated virus (HTLV-III)]. (1984) (0)
Immunoglobulin Expression in B-Cell Leukemias and B-Cell Lymphomas (1980) (0)
Antibodies to tissue antigens in cases of Mycoplasma pneumoniae infection. (1970) (0)
Animal oncoviruses (2006) (0)
Predictive Markers of Mother-to-Child Transmission of HIV-1 in Tanzania (1993) (0)
MOTHER TO CHILD TRANSMISSION OF HIV—ANTIRETROVIRAL THERAPY AND THERAPEUTIC VACCINE: A SCIENTIFIC AND COMMUNITY CHALLENGE (2002) (0)
P19-20. Allogeneic stimulation of the anti-viral APOBEC3G in human CD4+ T cells and prevention of SHIV infectivity in macaques immunized with HLA antigens (2009) (0)
The Prevalence, Incidence, and Risk Factors for HIV Among Female Sex Workers—A Cohort Being Prepared for a Phase IIb HIV Vaccine Trial in Dar es Salaam, Tanzania (2022) (0)
[Diagnosis and antinuclear antibodies - a review]. (1982) (0)
CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization (2012) (0)
Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen (2012) (0)
Astrid Fagraeus, 1913–1997 (1998) (0)
Rapid Communication Malignant Lymphomas inCynomolgus Monkeys Infected withSimian Immunodeficiency Virus (1990) (0)
Comparative studies of endemic and epidemic Kaposi's sarcoma in Tanzania (2007) (0)
[Clinical and serological aspects of chronic active hepatitis]. (1971) (0)
LYMPHOMA DEVELOPMENT IN SIV INFECTED MONKEYS: 141 (1997) (0)
146 Strong and Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Prime MVA Boost Vaccine Regimen Among Healthy Tanzanian Volunteers (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gunnel Biberfeld?

Gunnel Biberfeld is affiliated with the following schools:

Gunnel Biberfeld's Academic­Influence.com Rankings

Why Is Gunnel Biberfeld Influential?

Gunnel Biberfeld's Published Works

Published Works

What Schools Are Affiliated With Gunnel Biberfeld?

Gunnel Biberfeld's AcademicInfluence.com Rankings